PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.

@article{Palermo2018PTH134FS,
  title={PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.},
  author={Andrea Palermo and Assunta Santonati and Gaia Tabacco and Daniela Bosco and Antonio Spada and Claudio Pedone and Bruno Raggiunti and Tina Doris and Daria Maggi and Franco Grimaldi and Silvia Manfrini and F Vescini},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2018},
  volume={103 1},
  pages={
          271-280
        }
}
Context Daily parathyroid hormone (PTH) (1-34) administrations can reduce the required total daily dose of calcium and calcitriol and restore normocalcemia in refractory hypoparathyroidism. However, most PTH(1-34) trials have been conducted on small cohorts including subjects with hypoparathyroidism of various etiologies, and quality of life (QOL) was not investigated. Objective To investigate the effects of 24-month PTH(1-34) treatment in a homogeneous cohort of adult subjects with… CONTINUE READING
4
Twitter Mentions

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Management of Hypoparathyroidism: Summary Statement and Guidelines.

  • The Journal of clinical endocrinology and metabolism
  • 2016
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2016